Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

ClinicalTrials.gov ID: NCT00331630

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00331630. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane together with lapatinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving Abraxane together with lapatinib works in treating patients with stage I, stage II, or stage III breast cancer.

Study identification

NCT ID: NCT00331630
Recruitment status: Completed
Study type: Interventional
Phase: Early Phase 1
Lead sponsor: Northwestern University; Other
Enrollment: 30 participants

Conditions and interventions

Conditions

Breast Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 4, 2006 (Actual)
Primary completion: Nov 10, 2006 (Actual)
Completion: Aug 5, 2010 (Actual)
Last update posted: Mar 6, 2020

2006 – 2010

United States locations

U.S. sites: 5
U.S. states: 2
U.S. cities: 4

Facility	City	State	ZIP	Site status
Northwestern University, Northwestern Medical Faculty Foundation	Chicago	Illinois	60611-3013	—
Hematology-Oncology Associates of Illinois	Chicago	Illinois	60611	—
Midwest Center for Hematology/Oncology	Joliet	Illinois	60432	—
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields	Olympia Fields	Illinois	60461	—
Joe Arrington Cancer Research and Treatment Center	Lubbock	Texas	79410-1894	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00331630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 6, 2020 · Synced Nov 12, 2026